Capital One analyst Naureen Quibria initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight rating and announces Price Target of $40.
Barrington Research analyst Vincent Colicchio initiates coverage on Alithya Group (NASDAQ:ALYA) with a Outperform rating and announces Price Target of $3.5.